Holen Sie sich die Stockscreener-App
3.04
0.00%
0.00
Vorhandelsmarkt:
3.10
0.06
+1.97%
Schlusskurs vom Vortag:
$3.04
Offen:
$2.98
24-Stunden-Volumen:
9,652
Relative Volume:
0.57
Marktkapitalisierung:
$13.23M
Einnahmen:
$1.19M
Nettoeinkommen (Verlust:
$-2.15M
KGV:
-16.80
EPS:
-0.1809
Netto-Cashflow:
$-8.17M
1W Leistung:
+15.59%
1M Leistung:
+37.56%
6M Leistung:
-12.64%
1J Leistung:
-6.46%
1-Tages-Spanne:
$2.98
$3.0699
1-Wochen-Bereich:
$2.6101
$3.1695
52-Wochen-Spanne:
$2.15
$7.7699
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
Firmenname
Bioline Rx Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare BLRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLRX
Bioline Rx Ltd Adr
|
3.04 | 13.23M | 1.19M | -2.15M | -8.17M | -0.1809 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2017-05-18 | Hochstufung | Maxim Group | Hold → Buy |
| 2017-02-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-08-12 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-08-17 | Bestätigt | Maxim Group | Buy |
| 2015-07-27 | Bestätigt | ROTH Capital | Buy |
| 2015-06-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Bioline Rx Ltd Adr Aktie (BLRX) Neueste Nachrichten
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI) - The Globe and Mail
BioLineRx and Hemispherian Dose First Patient in Phase 1/2a GLIX1 Glioblastoma Trial - TipRanks
BioLineRx doses first patient in glioblastoma drug trial By Investing.com - Investing.com South Africa
BioLineRx doses first patient in glioblastoma drug trial - Investing.com
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - Barchart.com
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR) - The Globe and Mail
Analysts’ Top Healthcare Picks: Rapport Therapeutics, Inc. (RAPP), Abbott Laboratories (ABT) - The Globe and Mail
BioLineRx: Advancing GLIX1 and Motixafortide Pipeline with Strengthened IP and Legal Position Underpinning Buy Rating and $12 Target - TipRanks
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR), Alto Neuroscience, Inc. (ANRO) and Viridian Therapeutics (VRDN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT) - The Globe and Mail
Operating cash flow per share of BioLineRX Ltd. Sponsored ADR – MUN:YP2 - TradingView
BioLineRx launches trial of brain cancer drug GLIX1 By Investing.com - Investing.com South Africa
BioLineRx initiates Phase 1/2a study of GLIX1 - tipranks.com
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - Finviz
BioLineRx Launches First-in-Human Trial of GLIX1 for Glioblastoma - TipRanks
BioLineRx launches trial of brain cancer drug GLIX1 - investing.com
BioLineRx provides corporate update - tipranks.com
Earnings call transcript: BioLineRx’s Q4 2025 sees revenue drop, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: BioLineRx’s Q4 2025 sees revenue drop, stock dips - Investing.com
BioLineRx Reports 2025 Financial Results and Provides Corporate Update - Finviz
BioLineRx Sets March Start for GLIX1 Brain Cancer Trial as 2025 Results Show Leaner R&D-Focused Model - TipRanks
Going concern and debt pressures at BioLineRx (NASDAQ: BLRX) - Stock Titan
Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings - Sahm
BioLineRx to Report 2025 Annual Results on March 23, 2026 - Finviz
BioLineRx Wins Arbitration Ruling in Motixafortide Licensing Dispute - TipRanks
Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Beyond Air (XAIR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW), Icon (ICLR) and Perspective Therapeutics (CATX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Radiopharm Theranostics Limited Sponsored ADR (RADX) and Resmed (RMD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: MBX Biosciences, Inc. (MBX), Praxis Precision Medicines (PRAX) and Iovance Biotherapeutics (IOVA) - The Globe and Mail
BioLineRx Earnings Call: Strategic Initiatives Amid Revenue Challenges - MSN
BioLineRx Reports Q3 2025 Results and Strategic Expansion - TipRanks
Earnings call transcript: BioLineRx Q3 2025 earnings reveal significant revenue miss By Investing.com - Investing.com South Africa
BioLineRx Announces Q3 2025 Financial Results and New Joint Venture - TipRanks
Earnings call transcript: BioLineRx Q3 2025 earnings reveal significant revenue miss - Investing.com India
BioLineRx shares rise over 7% on better-than-expected earnings By Investing.com - Investing.com South Africa
BioLineRx shares rise over 7% on better-than-expected earnings - Investing.com
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Finviz
BioLine Rx's Earnings: A Preview - Sahm
BioLineRx stock rises after partner receives key patent allowance By Investing.com - Investing.com India
BioLineRx stock rises after partner receives key patent allowance - Investing.com
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 - Finviz
BioLineRx stock rises after securing key patent for cancer treatment - Investing.com India
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types - Finviz
BioLineRx Secures USPTO Patent Allowance for Cancer Treatment with GLIX1 - TipRanks
BioLineRx receives key patent for cancer treatment GLIX1 - Investing.com India
BioLineRx receives key patent for cancer treatment GLIX1 By Investing.com - Investing.com South Africa
Finanzdaten der Bioline Rx Ltd Adr-Aktie (BLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):